NeuroKaire's mission is to transform brain health and eliminate suffering through the integration of precision medicine into psychiatry and neurology. Through a simple blood test, NeuroKaire’s neuronal readout provides a new window into brain function, helping clinicians identify the optimal antidepressant based on the unique response of a patient's brain cells combined with their genetics and medical history. By eliminating trial-and-error protocols and optimizing treatments, NeuroKaire significantly improves patient outcomes and reduces side effects. The company’s innovative technology also provides pharmaceutical companies with essential tools for targeted drug discovery and development. Stay connected and learn more about our mission to revolutionize mental health: https://linktr.ee/NeuroKaire
Company Details
- Employees
- 45
- Founded
- -
- Address
- 126 Yigal Alon Street, Wing C,floor 2,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://linktr.ee/NeuroKaire
- Keywords
- Biotechnology, Neuroscience, Mental Illness, ww.
- HQ
- Tel Aviv
Neurokaire (Formerly Genetika+) Questions
Neurokaire (Formerly Genetika+)'s website is https://linktr.ee/NeuroKaire
Neurokaire (Formerly Genetika+)'s LinkedIn profile is https://www.linkedin.com/company/neurokaire
Neurokaire (Formerly Genetika+) has
45 employees.
View email and phone details for 45
employees at Neurokaire (Formerly Genetika+).
Neurokaire (Formerly Genetika+)'s industry is
Biotechnology Research
Neurokaire (Formerly Genetika+)'s top competitors are
Anima Biotech,
Cytoreason,
Imagene,
Immunai,
Evogene,
Nucleai,
Biomx (Nyse: Phge),
Protai,
Memed,
Aidoc.
Neurokaire (Formerly Genetika+)'s categories are Biotechnology Research
Neurokaire (Formerly Genetika+)'s founding year is 2017
